Allen Institute Launches Brain Health Accelerator for Genetic Therapies
Similar Articles
Research Identifies Protein Target That Improves Memory in Alzheimer's Mouse Model
NIH Bridge Funding Sustains Alzheimer's Research Network After Grant Rejection
Experimental Compounds Show Promise in Reducing Brain Inflammation Linked to Alzheimer's
Engineered Nanoparticles Show Promise in Restoring Brain Waste Removal in Alzheimer's Mouse Model
Amino Acid Supplement Boosts mRNA Delivery and Gene Editing Efficiency
The Allen Institute has launched the Brain Health accelerator, a collaborative initiative focused on developing new genetic therapies for brain disorders. The effort builds on the federal BRAIN Initiative and aims to create treatments for diseases like Alzheimer's, Parkinson's, ALS, and Huntington's.
Facts First
- The Brain Health accelerator is a new collaborative initiative launched by the Allen Institute
- The initiative plans to develop genetic therapies for Alzheimer's, Parkinson's, ALS, and Huntington's disease
- The effort is an outgrowth of the federal BRAIN Initiative, a public-private partnership unveiled in 2013
- Genetic therapies have already shown success in treating spinal muscular atrophy
- The Allen Institute maintains a policy of making its databases available globally
What Happened
The Allen Institute has launched the Brain Health accelerator, a collaborative effort in Seattle. The initiative plans to develop new genetic therapies... for diseases such as Alzheimer's, Parkinson's, ALS, and Huntington's. The Brain Health accelerator is an outgrowth of the BRAIN Initiative, a public-private partnership unveiled by President Obama in 2013 intended to create tools for seeing the brain's inner workings and developing treatments.
Why this Matters to You
If you or a family member are affected by a brain disorder like Alzheimer's, Parkinson's, ALS, or Huntington's disease, this initiative could lead to new treatment options in the coming years. The focus on genetic therapies builds on a proven approach, as these therapies have already successfully treated spinal muscular atrophy. The Allen Institute's policy of making its databases available globally means scientists everywhere may be able to contribute to this research, potentially accelerating progress.
What's Next
The Brain Health accelerator will likely begin its work on developing specific genetic therapies for the targeted diseases. Scientists involved, like Jeff Carroll who carries the Huntington's gene and studied mice with the disease, may apply their research directly to these efforts. The collaborative nature of the initiative and its connection to the broader BRAIN Initiative could help streamline the path from research to treatment.